

Figure S1.




Figure S1. Frequency of effector T_{reg} cells among total T_{reg} cells defined as $CD25^+CD127^{-/low}$ or $CD25^+CD127^{-/low}Foxp3^+$ is decreased in PBMCs of RA patients. Blood samples were collected from healthy donors (HC, $n = 13$) and RA patients (RA, $n = 13$) and T_{reg} cell subpopulations were analyzed by flow cytometry. (A) Representative plots show the gating strategy used to identify subgroup I ($CD25^{int}CD45RA^+$ cells), II ($CD25^{hi}CD45RA^-$ cells), and III ($CD25^{int}CD45RA^-$ cells) in $CD25^+CD127^{-/low}$ or $CD25^+CD127^{-/low}Foxp3^+$ T_{reg} cells by flow cytometry. (B) Frequency of subgroup I, II, and III in T_{reg} cells defined by $CD25^+CD127^{-/low}$. (C) Frequency of subgroup I, II, and III in T_{reg} cells defined by $CD25^+CD127^{-/low}Foxp3^+$. Statistical differences were calculated by Mann-Whitney test.

Figure S2.




Figure S2. Frequency of effector T_{reg} cells among CD25⁺Foxp3⁺ T_{reg} cells is decreased in PBMCs of RA patients. (A) Representative plots show the gating strategy used to identify subgroup I (CD25^{int}CD45RA⁺ cells), II (CD25^{hi}CD45RA⁻ cells), and III (CD25^{int}CD45RA⁻ cells) in CD25⁺Foxp3⁺ Treg cells by flow cytometry. FMO (fluorescence minus one control); HC (healthy control). (B) Frequency of subgroup I, II, and III in CD25⁺Foxp3⁺ T_{reg} cells of PBMCs from healthy controls (HC, n = 13) and RA patients (RA, n = 13). Statistical differences were calculated by Mann-Whitney test.


Figure S3.

Figure S3. Naïve and effector T_{reg} cells from RA patients show decreased CD25 expression. Expression of CD25 and Foxp3 was measured by flow cytometry in T_{reg} cell subgroups I (CD25^{int}CD45RA⁺ cells), II (CD25^{hi}CD45RA⁻ cells), and III (CD25^{int}CD45RA⁻ cells) in PBMCs from healthy controls (HC, n = 13) and RA patients (RA, n = 13). T_{reg} cells were defined as (A) CD25⁺Foxp3⁺, (B) CD25⁺CD127^{-low}, or (C) CD25⁺CD127^{-low}Foxp3⁺. Statistical differences were calculated by Mann-Whitney test.

Table S1. Characteristics of Controls and RA subjects

Variables	Controls (N = 13)	RA subjects (N = 13)	Unit
Gender	9 (69.2 %)	9 (69.2 %)	Female n (%)
Age	43 (26-70)	52 (22-78)	Median yr (range ¹)
Body-mass index ²	22.4 (19.4-28.1)	20.2 (17.7-31.6)	Median (range ¹)
Disease activity (DAS28 score)	na ³	2.7 (0.5-4.5)	Median (range ¹)
Remission (< 2.6)		6 (46.2)	N (%)
Mild (2.6-3.2)		2 (15.4)	N (%)
Moderate (3.2-5.1)		5 (38.4)	N (%)
Severe (>5.1)		0 (0)	N (%)

¹ Minimum to maximum

² Body-mass index is the weight in kilograms divided by the square of the height in meters.

³ not applicable